Drug news

Biogen and Abbvie withdraw Zinbryta a treatment for relapsing multiple sclerosis.

Read time: 1 mins

Last updated:3rd Mar 2018

Published:3rd Mar 2018

Source: Pharmawand

Biogen and AbbVie announced the voluntary worldwide withdrawal of Zinbryta for relapsing multiple sclerosis. The companies believe that characterizing the complex and evolving benefit/risk profile of Zinbryta will not be possible going forward given the limited number of patients being treated. Biogen will continue to work collaboratively with regulatory authorities in the withdrawal of product and with healthcare providers worldwide in their support of Zinbryta patients.

Learning Zone Homepage

Multiple Sclerosis (MS) Learning Zone

Choosing the right treatment is critical to managing multiple sclerosis (MS). Consider your options with the latest data from over 40 MS clinical trial and congress resources.

Learning Zones

The Learning Zones are an educational resource for healthcare professionals that provide medical information on the epidemiology, pathophysiology and burden of disease, as well as diagnostic techniques and treatment regimens.

Click here to view

Related news and insights

Drug news

FDA approves high-concentration, citrate-free formulation of Cyltezo (adalimumab-adbm) injection, interchangeable biosimilar to Humira

Boehringer Ingelheim announced that the FDA has approved the high-concentration, citrate-free formulation of Cyltezo (adalimumab-adbm), the company’s interchangeable* biosimilar to Humira (adalimumab), to treat multiple chronic inflammatory diseases

1 mins

Drug news

FDA approval for Inceptiv closed-loop spinal cord stimulator stimulator (SCS)for the treatment of chronic pain

Medtronic plc announced that the FDA has approved the Inceptiv closed-loop rechargeable spinal cord stimulator (SCS) for the treatment of chronic pain

1 min

Drug news

The FDA has approved the Esprit BTK Everolimus Eluting Resorbable Scaffold System (Esprit BTK System), a breakthrough innovation for people with chronic limb-threatening ischemia below-the-knee

Abbott announced that the FDA has approved the Esprit BTK Everolimus Eluting Resorbable Scaffold System (Esprit BTK System), a breakthrough innovation for people with chronic limb-threatening ischemia (CLTI) below-the-knee (BTK)

2 min

See all news